改进的功能状态问卷评估匹马万色林治疗帕金森病精神病患者：事后分析

IF 3.9 3区医学 Q1 CLINICAL NEUROLOGY

Neurology and Therapy Pub Date : 2025-05-12 DOI:10.1007/s40120-025-00757-3

Virgilio G H Evidente, Lambros Chrones, Ratna Revankar, Dilesh Doshi, Victor Abler, Nazia Rashid

{"title":"改进的功能状态问卷评估匹马万色林治疗帕金森病精神病患者：事后分析","authors":"Virgilio G H Evidente, Lambros Chrones, Ratna Revankar, Dilesh Doshi, Victor Abler, Nazia Rashid","doi":"10.1007/s40120-025-00757-3","DOIUrl":null,"url":null,"abstract":"Introduction: Over half of patients with Parkinson's disease experience psychosis (PDP) symptoms over the course of their disease. In addition to significantly impacting patients' health-related quality of life and cognitive abilities, these symptoms impact patients' activities of daily living (ADLs) and overall functional status. Clinical assessment of how psychosis impacts these measures is crucial; however, few studies have assessed functional status among patients with PDP. A previous phase 4 study assessing the impact of pimavanserin on ADLs in patients with PDP demonstrated that a modified version of the Functional Status Questionnaire (mFSQ) could be used for this purpose. This post hoc analysis aimed to demonstrate the utility of the mFSQ as a patient-reported outcomes tool and to expand on initial study findings by showing the impact of pimavanserin on ADLs and functional status for each mFSQ subscale.Methods: An analysis of mFSQ data was conducted on patients with PDP treated with pimavanserin. This analysis evaluated the least-squares mean (LSM) change from baseline to week 16 on the mFSQ by subscale (basic ADL, intermediate ADL, psychological function, quality of interaction, and social activity). Pearson's correlation was used to assess the relationship between results from the mFSQ and the well-established Schwab and England ADL scale.Results: In this assessment (n = 29), treatment with pimavanserin was associated with improvements on all 5 domains of the mFSQ, highlighting a broad improvement in ADLs and function. The greatest LSM (SE) improvement was seen in the social activity subscale [25.8 (7.52); 95% CI 10.2-41.5; p = 0.0026]. The mFSQ results demonstrated positive correlations with patient- and caregiver-rated Schwab and England ADL scales.Conclusion: This analysis provides additional information about the impact of treatment with pimavanserin on specific mFSQ subscales. Additionally, the mFSQ was significantly correlated with the patient- and the caregiver-rated Schwab and England ADL scales.","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Modified Functional Status Questionnaire for Assessing Patients with Parkinson's Disease Psychosis Treated with Pimavanserin: A Post Hoc Analysis.\",\"authors\":\"Virgilio G H Evidente, Lambros Chrones, Ratna Revankar, Dilesh Doshi, Victor Abler, Nazia Rashid\",\"doi\":\"10.1007/s40120-025-00757-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Over half of patients with Parkinson's disease experience psychosis (PDP) symptoms over the course of their disease. In addition to significantly impacting patients' health-related quality of life and cognitive abilities, these symptoms impact patients' activities of daily living (ADLs) and overall functional status. Clinical assessment of how psychosis impacts these measures is crucial; however, few studies have assessed functional status among patients with PDP. A previous phase 4 study assessing the impact of pimavanserin on ADLs in patients with PDP demonstrated that a modified version of the Functional Status Questionnaire (mFSQ) could be used for this purpose. This post hoc analysis aimed to demonstrate the utility of the mFSQ as a patient-reported outcomes tool and to expand on initial study findings by showing the impact of pimavanserin on ADLs and functional status for each mFSQ subscale.Methods: An analysis of mFSQ data was conducted on patients with PDP treated with pimavanserin. This analysis evaluated the least-squares mean (LSM) change from baseline to week 16 on the mFSQ by subscale (basic ADL, intermediate ADL, psychological function, quality of interaction, and social activity). Pearson's correlation was used to assess the relationship between results from the mFSQ and the well-established Schwab and England ADL scale.Results: In this assessment (n = 29), treatment with pimavanserin was associated with improvements on all 5 domains of the mFSQ, highlighting a broad improvement in ADLs and function. The greatest LSM (SE) improvement was seen in the social activity subscale [25.8 (7.52); 95% CI 10.2-41.5; p = 0.0026]. The mFSQ results demonstrated positive correlations with patient- and caregiver-rated Schwab and England ADL scales.Conclusion: This analysis provides additional information about the impact of treatment with pimavanserin on specific mFSQ subscales. Additionally, the mFSQ was significantly correlated with the patient- and the caregiver-rated Schwab and England ADL scales.\",\"PeriodicalId\":19216,\"journal\":{\"name\":\"Neurology and Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-05-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40120-025-00757-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40120-025-00757-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

简介：超过一半的帕金森病患者在他们的疾病过程中经历精神病（PDP）症状。除了显著影响患者健康相关的生活质量和认知能力外，这些症状还会影响患者的日常生活活动（ADLs）和整体功能状态。精神病如何影响这些措施的临床评估是至关重要的；然而，很少有研究评估PDP患者的功能状态。先前的一项评估匹马万色林对PDP患者adl影响的4期研究表明，功能状态问卷（mFSQ）的修改版本可用于此目的。本事后分析旨在证明mFSQ作为患者报告结果工具的效用，并通过显示匹马万塞林对adl和每个mFSQ子量表的功能状态的影响来扩展初始研究结果。方法：对匹马万塞林治疗的PDP患者的mFSQ数据进行分析。本分析通过子量表（基本ADL、中间ADL、心理功能、互动质量和社会活动）评估从基线到第16周mFSQ的最小二乘平均值（LSM）变化。Pearson’s相关性用于评估mFSQ结果与公认的Schwab和England ADL量表之间的关系。结果：在这项评估中（n = 29），使用匹马万色林治疗与mFSQ的所有5个结构域的改善相关，突出了adl和功能的广泛改善。LSM （SE）改善最大的是社会活动分量表[25.8 (7.52)]；95% ci 10.2-41.5；p = 0.0026]。mFSQ结果显示与患者和护理人员评定的Schwab和英格兰ADL量表呈正相关。结论：该分析提供了关于匹马万塞林治疗对特定mFSQ亚量表影响的额外信息。此外，mFSQ与患者和护理者评定的Schwab和England ADL量表显著相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Modified Functional Status Questionnaire for Assessing Patients with Parkinson's Disease Psychosis Treated with Pimavanserin: A Post Hoc Analysis.

Introduction: Over half of patients with Parkinson's disease experience psychosis (PDP) symptoms over the course of their disease. In addition to significantly impacting patients' health-related quality of life and cognitive abilities, these symptoms impact patients' activities of daily living (ADLs) and overall functional status. Clinical assessment of how psychosis impacts these measures is crucial; however, few studies have assessed functional status among patients with PDP. A previous phase 4 study assessing the impact of pimavanserin on ADLs in patients with PDP demonstrated that a modified version of the Functional Status Questionnaire (mFSQ) could be used for this purpose. This post hoc analysis aimed to demonstrate the utility of the mFSQ as a patient-reported outcomes tool and to expand on initial study findings by showing the impact of pimavanserin on ADLs and functional status for each mFSQ subscale.

Methods: An analysis of mFSQ data was conducted on patients with PDP treated with pimavanserin. This analysis evaluated the least-squares mean (LSM) change from baseline to week 16 on the mFSQ by subscale (basic ADL, intermediate ADL, psychological function, quality of interaction, and social activity). Pearson's correlation was used to assess the relationship between results from the mFSQ and the well-established Schwab and England ADL scale.

Results: In this assessment (n = 29), treatment with pimavanserin was associated with improvements on all 5 domains of the mFSQ, highlighting a broad improvement in ADLs and function. The greatest LSM (SE) improvement was seen in the social activity subscale [25.8 (7.52); 95% CI 10.2-41.5; p = 0.0026]. The mFSQ results demonstrated positive correlations with patient- and caregiver-rated Schwab and England ADL scales.

Conclusion: This analysis provides additional information about the impact of treatment with pimavanserin on specific mFSQ subscales. Additionally, the mFSQ was significantly correlated with the patient- and the caregiver-rated Schwab and England ADL scales.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Neurology and Therapy CLINICAL NEUROLOGY-

CiteScore

5.40

自引率

8.10%

发文量

103

审稿时长

6 weeks

期刊介绍： Aims and Scope Neurology and Therapy aims to provide reliable and inclusive, rapid publication for all therapy related research for neurological indications, supporting the timely dissemination of research with a global reach, to help advance scientific discovery and support clinical practice. Neurology and Therapy is an international, open access, peer reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world and health outcomes research around the discovery, development, and use of neurological and psychiatric therapies, (also covering surgery and devices). Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also welcomed. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, case reports, trial designs, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Neurology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted, it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model, this allows for the rapid and efficient communication of the latest research and reviews to support scientific discovery and clinical practice. Open Access All articles published by Neurology and Therapy are open access. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Digital Features and Plain Language Summaries Neurology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/ Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case-by-case basis. Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials and Letters which are generally reviewed by one member of the Editorial Board. Where reviews conflict, an Editorial Board Member will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed. Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised, it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor, and authors are welcome to make rebuttals against individual reviewer comments, if appropriate. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors'' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Copyright Neurology and Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Contact For more information about the journal, including pre-submission enquiries, please contact managing editor Lydia Alborn at lydia.alborn@springer.com.